HELP FOR FIP® TREATMENT SUPPORT HANDBOOK

What is GS441524 and What Is the Approval Status?

GS-441524 is a nucleoside analogue antiviral drug that Gilead Sciences developed. It is the primary plasma metabolite of the antiviral prodrug Remdesivir, developed for human use.

Remdesivir and GS-441524 were both effective in vitro against feline coronavirus strains that cause FIP. Remdesivir was never tested in cats, although it's used in other countries.

GS-441524 is an effective treatment for FIP and is widely used despite no official FDA approval due to Gilead's refusal to license this drug for veterinary use.

As many people report, the FDA is NOT to blame for the lack of an available, prescribable cure. Therefore, it's unfair to scrutinize parents seeking off-market FIP treatment often at their veterinarian's recommendation. The ethical nature of their oath drives many veterinarians to advise their clients to find it. Cat owners desperately want to save their beloved family pet and have no choice but to find it themselves (continue reading for the newest developments).

Gilead Sciences holds the patent, aka "the key" to curing tens of thousands of cats globally.

However, they chose not to proceed with FDA approval to make it legally available to prescribing veterinarians after the successful UC Davis 2017 drug trial. Here's their reasoning: Gilead Sciences is known for its antiviral drugs for treating HIV/AIDS, hepatitis B and C, influenza, and COVID-19. Gilead refuses to license the drug for animal use, fearing its similarity to Remdesivir (originally developed to treat Ebola) would interfere with the FDA approval process.

Chinese companies and others worldwide started manufacturing the GS compound to sell via various avenues. **A word of caution: Not all GS brands are created equal. Be cautious of the first attractive websites in a Google search or the unsolicited texts or emails from persuasive scammers. You can always ask us about off-market brand legitimacy. Laboratory testing data is available upon request for some brands, and results may include purity, concentration, consistency, and pH (acidity) testing.

While the media zeroes in on the cost of this life-saving treatment, they neglect to report on affordability and safety, especially in the last few years. Compared to 2019, the price of GS has drastically reduced, making it affordable to most. As of June 1, 2024, veterinarians can prescribe oral GS-441524 ORAL compounds (not injectables) under a specific FDA rule.

While still illegal and unapproved, the FDA allows risk-free compound prescribing.

Page 4